| 2013 | | A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer. | 강석윤 |
| 2017 | | A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer | 강석윤 |
| 2022 | | BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis | 노진, 정성현, 최윤석 |
| 1997 | | Bilateral primary renal non-Hodgkin's lymphoma presenting with acute renal failure: successful treatment with systemic chemotherapy. | 최진혁 |
| 1996 | | Concurrent presentation of erythrocytic and megakaryocytic aplasia. | 김효철 |
| 2001 | | Cyclophosphamide - Induced lung toxicity in a patient with Wegener`s granulomatosis | 김흥수, 박경주, 신규태, 임현이, 한명호 |
| 2011 | | Cyclophosphamide-induced lupus flare?: the role of C4 and interferon-gamma in lupus flare. | 박세진 |
| 2020 | | Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer | 정용식 |
| 2016 | | High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy | 강석윤, 김장희, 박준성, 신승수, 안미선, 이현우, 정성현, 최용원, 최진혁, 한재호 |
| 2016 | | Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of 2 Multicenter Prospective Studies | 박준은, 정현주 |
| 2023 | | Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study | 박준성 |
| 2019 | | Loperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death | 최경숙, 최용원 |
| 2015 | | Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation. | 정성현 |
| 2018 | | Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil | 김현아, 서창희 |
| 1997 | | P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. | 이기범 |
| 2014 | | Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. | 강석윤, 박준성, 안미선, 이현우, 정성현, 최용원, 최진혁 |
| 2022 | | Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study | 정성현, 최윤석 |
| 2019 | | Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study | 정성현 |
| 2024 | | Prediction of immunochemotherapy response for diffuse large B-cell lymphoma using artificial intelligence digital pathology | 노명균 |
| 2015 | | Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients. | 고영화 |
| 2012 | | Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) | 정성현 |
| 2016 | | Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study | 강석윤 |
| 2020 | | Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2 | 노진, 박준성, 정성현, 한재호 |
| 2016 | | Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF | 박준성 |
| 2010 | | Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study. | 박준은 |
| 2007 | | Successful treatment of pediatric systemic polyarteritis nodosa with cholestatic hepatitis. | 박해심, 서창희, 예영민 |
| 2009 | | Topotecan/Cycophosphamide Salvage Chemotherapy in Children with Recurrent or Refractory Solid Tumors | 박준은, 정현주 |
